到 2028 年經皮中樞神經系統 (CNS) 治療市場

這份報告考察了透皮中樞神經系統 (CNS) 治療市場，提供了市場概述、技術趨勢、需求驅動因素、按細分市場劃分的藥物趨勢以及進入市場的公司概況。我正在整理。

內容

• 執行摘要
• 到 2028 年將出現經皮中樞神經系統藥物
• 市場機會
• 透皮給藥動力學
• 需求驅動因素
• 貼片製造動態
• 離型紙
• 背襯膜
• 半透膜
• 粘合劑
• 透皮中樞神經系統藥物市場
• 多動症
• 戴特拉納
• □甲酯（Daytrana - 諾文）
• 阿爾茨海默病
• 卡巴拉汀（Exelon - 諾華）
• Aricept 透皮吸收劑 - 近期活動
• 艾克賽隆
• 抑鬱症
• 抗抑鬱藥
• 司來吉蘭（EMSAM - 邁蘭）
• 噁心
• 生物鹼
• 東莨菪鹼 (Transderm Scop) 葛蘭素史克消費者健康
• 格拉司瓊（Sancuso - ProStrakan）
• 帕金森病
• 左旋多巴
• 羅替戈汀（Neupro - Schwarz/UCB））
• 精神分裂症
• 阿塞那平（Secuado - 諾文）
• 透皮中樞神經系統藥物分析及市場評價
• FDA 批准的透皮中樞神經系統處方產品
• 中樞神經系統興奮劑
• 乙□膽鹼酯□抑製劑
• 非典型抗精神病藥
• 生物鹼
• 多巴胺激動劑
• 5-HT3受體拮抗劑
• MAO抑製劑
• 戰略因素和品牌問題
• 多巴胺激動劑
• 公司簡介

“Transdermal CNS Therapeutics to 2028: Products, Therapeutics, Markets and Forecasts” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, patch designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for Transdermal patches Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Converging Factors Driving Growth in Transdermal Delivery

Transdermal CNS drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Growth in demand for drug patches is being driven by several factors - factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2028.

What You Will Learn:

• Analyzes and evaluates current transdermal CNS therapeutics markets and products and assesses the market potential for existing and probable future products

• Analyzes patch designs, technologies and patch development issues

• Profiles patch manufacturers and third-party transdermal supply chain companies

• Provides detailed assessments of more than a dozen products in more than a dozen product categories

• Provides market data and forecasts to 2028

• Profiles transdermal drug patch product providers, their product development activity, and strategies

• Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

• Executive Summary
• Transdermal CNS Therapeutics to 2028
• The Market Opportunity
• Transdermal Drug Delivery Dynamics
• Demand Drivers
• Patch Manufacturing Dynamics
• Release Liners
• Backing Films
• Semi-permeable Membranes
• Adhesives
• Markets for Transdermal CNS Therapeutics
• ADHD
• Daytrana
• Methylphenidate (Daytrana - Noven)
• Alzheimer's Disease
• Rivastigmine (Exelon - Novartis)
• Aricept Transdermal - Recent Activity
• Exelon
• Depression
• Antidepressants
• Selegiline (EMSAM - Mylan)
• Nausea
• Alkaloids
• Scopolamine (Transderm Scop) GlaxoSmithKline Consumer Health
• Granisetron (Sancuso - ProStrakan)
• Parkinson's Disease
• Levodopa
• Rotigotine (Neupro - Schwarz/UCB))
• Schizophrenia
• Asenapine (Secuado - Noven)
• Transdermal CNS Drug Product Analysis and Market Assessments
• FDA Approved Transdermal CNS Prescription Products
• CNS Stimulants
• AChE Inhibitors
• Atypical Antipsychotics
• Alkaloids
• Dopamine Agonists
• 5-HT3 Receptor Antagonists
• MAO Inhibitors
• Strategic Factors and Branding Issues
• Dopamine Agonists
• Company Profiles